Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed. The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL). The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients (59% +/- 5% vs 88% +/- 1% 5-year EFS). Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Institute high-risk (NCI HR) patients who were MRD(+). The few patients with detectable MRD at end of consolidation fared especially poorly, with only a 43% plus or minus 7% 5-year EFS. Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis. The 12% of patients with all favorable risk factors, including NCI risk group, genetics, and absence of days 8 and 29 MRD, had a 97% plus or minus 1% 5-year EFS with nonintensive therapy. These studies are registered at www.clinicaltrials.gov as NCT00005585, NCT00005596, and NCT00005603.

[1]  A. Look,et al.  Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. , 1992, Blood.

[2]  J. V. van Dongen,et al.  Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.

[3]  P. Martiat,et al.  A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse , 1997, British journal of haematology.

[4]  H. Sather,et al.  Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Cavé,et al.  Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. , 2005, Haematologica.

[6]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[7]  A. Órfão,et al.  BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL) , 2000, Leukemia.

[8]  J. Dongen,et al.  Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia , 2004, Leukemia.

[9]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[10]  F. Behm,et al.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.

[11]  A. Look,et al.  Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse , 1999 .

[12]  C. Pui,et al.  Biology and Clinical Significance of Cytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia , 1990 .

[13]  A. Biondi,et al.  Minimal residual disease as a surrogate marker for risk assignment to ALL patients. , 2003, Reviews in clinical and experimental hematology.

[14]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[15]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[16]  A. Órfão,et al.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.

[17]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[18]  J. V. Dongen,et al.  Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL , 2002, Leukemia.

[19]  J. Condon,et al.  Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reaction , 1991, British journal of haematology.

[20]  M. Dworzak,et al.  Flow Cytometric Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia , 2003, Leukemia and Lymphoma.

[21]  C. V. D. Schoot,et al.  Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR , 2002, Leukemia.

[22]  D. Campana,et al.  Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.

[23]  J. Shuster,et al.  Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). , 2004 .

[24]  A. Órfão,et al.  Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. , 1994, Leukemia & lymphoma.

[25]  R. Foà,et al.  Outcome prediction by immunophenotypic minimal residual disease detection in adult T‐cell acute lymphoblastic leukaemia , 2003, British journal of haematology.

[26]  A Orfao,et al.  Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  George Davidson,et al.  Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. , 2006, Blood.

[28]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[29]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[30]  M. Schrappe,et al.  Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group , 2000, Leukemia.

[31]  H. Gadner,et al.  Detection of Residual Disease in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia by Comparative Phenotype Mapping: Method and Significance , 2000, Leukemia & lymphoma.

[32]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[33]  J. Downing,et al.  TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Campana,et al.  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[35]  M. Björkholm,et al.  Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL , 2001, Leukemia.

[36]  S. Sallan,et al.  Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment , 2003, Current opinion in hematology.

[37]  D. Campana,et al.  Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. , 2006, Haematologica.

[38]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[39]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.

[40]  J. Mazur,et al.  Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia , 2003, Leukemia.

[41]  M. Kneba,et al.  Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.

[42]  M. Loh,et al.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.

[43]  M. Schrappe,et al.  Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting , 2007, Leukemia.

[44]  H. Sather,et al.  Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. van der Burg,et al.  Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. , 2002, Blood.

[46]  H. Gschaidmeier,et al.  Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment , 2003, Leukemia.

[47]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[48]  L. Foroni,et al.  Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.

[49]  A. Morley,et al.  Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Órfão,et al.  Immunologic monitoring in adults with acute lymphoblastic leukemia , 2003, Current oncology reports.

[51]  J. Gribben,et al.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. , 2007, Blood.

[52]  D.,et al.  Regression Models and Life-Tables , 2022 .

[53]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[54]  M. Björkholm,et al.  Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping , 2004, Leukemia.

[55]  C. Eckert,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.

[56]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[57]  C. E. van der Schoot,et al.  Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse. , 2000, Blood.

[58]  E. Weir,et al.  A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection , 1999, Leukemia.

[59]  D. Campana,et al.  Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.

[60]  D. Campana,et al.  The use of flow cytometry to detect minimal residual disease in acute leukemia. , 1996, European journal of histochemistry : EJH.

[61]  E. Koníková,et al.  Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia. , 1996, Neoplasma.

[62]  M. Schrappe,et al.  MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen , 2001, Leukemia.

[63]  L. Foroni,et al.  Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Catovsky,et al.  Detection of minimal residual disease in B‐lineage acute lymphoblastic leukaemia by quantitative flow cytometry , 1998, British journal of haematology.

[65]  G. Specchia,et al.  Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia. , 2004, Haematologica.

[66]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[67]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[68]  J J Shuster,et al.  Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study , 2003, Leukemia.

[69]  D. Campana,et al.  Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. , 2001, Blood.

[70]  K. Schmiegelow,et al.  Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. , 2002, Blood.

[71]  D. Catovsky,et al.  Quantitative flow cytometry can distinguish between normal and leukaemic B‐cell precursors , 1995, British journal of haematology.

[72]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[73]  C. E. van der Schoot,et al.  Minimal residual disease studies are beneficial in the follow‐up of TEL/AML1 patients with B‐precursor acute lymphoblastic leukaemia , 2000, British journal of haematology.

[74]  P. Sirigu,et al.  Histochemical demonstration of acetylcholinesterase activity in human Meibomian glands. , 1996, European journal of histochemistry : EJH.